---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-079915"
form_type: "8-K"
ticker: "HOTH"
cik: "0001711786"
company_name: "Hoth Therapeutics, Inc."
filed_at: "2025-08-22T23:59:59+00:00"
generated_at: "2026-05-17T10:35:41.054687+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Hoth Therapeutics enters new CEO employment agreement with $550k salary and 800k share grant

## Summary
- CEO Robb Knie's new employment agreement includes $550,000 annual base salary and up to $550,000 annual bonus.
- 800,000 shares of common stock granted to Knie, vesting fully on grant date August 27, 2025.
- Agreement provides for transaction bonus tied to equity value if company engages in license, joint venture, or change of control.
- Company filed PCT patent application for HT-001, a topical treatment for side effects of cancer drugs, claiming priority to two U.S. provisionals.

## SEC filing metadata
- accession: 0001213900-25-079915
- form_type: 8-K
- ticker: HOTH
- cik: 0001711786
- company_name: Hoth Therapeutics, Inc.
- filed_at: 2025-08-22T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711786/000121390025079915/0001213900-25-079915-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711786/000121390025079915/ea0254112-8k_hoth.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-079915
- JSON: https://secwatch.observer/filing/0001213900-25-079915.json
- Plain text: https://secwatch.observer/filing/0001213900-25-079915.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.